Download Files:
EPI-7170
$280 – $2,350
Products Details
Product Description
– EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC)[1].
Web ID
– HY-150102
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C22H28Cl3NO6S
References
– [1]Hirayama Y, et al. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. 2020 Oct;14(10):2455-2470.
CAS Number
– 2139288-26-7
Molecular Weight
– 540.88
SMILES
– CC(C1=CC(Cl)=C(C(Cl)=C1)OC[C@H](O)CCl)(C2=CC=C(C=C2)OC[C@H](O)CNS(C)(=O)=O)C
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Androgen Receptor
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
